Tretazicar (Standard)
Tretazicar (Standard) is the analytical standard of Tretazicar. This product is intended for research and analytical applications. Tretazicar (CB 1954), an antitumor proagent, is highly selective against the Walker 256 rat tumour line. Tretazicar is enzymatically activated to generate a bifunctional agent, which can form DNA-DNA interstrand cross-links. Tretazicar in rat cells involves the reduction of its 4-nitro group to a 4-hydroxylamine by the enzyme NAD (P) H:quinone oxidoreductase 1 (NQO1) [1][2].
Product Specifications
CAS Number
21919-05-1
UNSPSC
12352100
Target
DNA Alkylator/Crosslinker; Reference Standards
Related Pathways
Cell Cycle/DNA Damage; Others
Field of Research
Cancer
Smiles
O=C(N)C1=CC(N2CC2)=C([N+]([O-])=O)C=C1[N+]([O-])=O
Molecular Formula
C9H8N4O5
Molecular Weight
252.18
References & Citations
[1]Knox RJ, et al. Bioactivation of 5- (aziridin-1-yl) -2,4-dinitrobenzamide (CB 1954) by human NAD (P) H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res. 2000 Aug 1;60 (15) :4179-86.|[2]Knox RJ, et al. CB 1954: from the Walker tumor to NQO2 and VDEPT. Curr Pharm Des. 2003;9 (26) :2091-104.|[3]Green NK, et al. Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronicadenovirus vector. Int J Cancer. 2003 Mar 10;104 (1) :104-12.|[4]Drabek D, et al. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. Gene Ther. 1997 Feb;4 (2) :93-100.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
bs-15076R-APC-Cy7 100 µL
C1orf77 Polyclonal Antibody, APC-Cy7 Conjugated
Sign In for Pricing
View Details 